Negative Points

• Evolent Health Inc ( NYSE:EVH )'s Q2 2026 medical expense ratio (MER) was 95%, up 200 basis points from Q1, reflecting the expected impact of the Highmark launch and higher acuity in exchange populations.

• The company faces significant headwinds in 2027, including an expected 20% decline in Medicaid expansion members, which translates to a 4-5% membership decline in Medicaid, and further exchange membership attrition.

• Evolent Health Inc ( NYSE:EVH ) expects Specialty Tech and Services revenue to be flat to down in 2027 due to membership headwinds, and the company is absorbing ongoing client-specific market exits and attrition.

• The company's operating cash flow in Q2 was unusually low due to the repayment of pass-through PBM proceeds, and full-year 2026 cash flow from operations is expected to be only $10-$20 million after interest expenses.

• Evolent Health Inc ( NYSE:EVH ) has a significant net debt of $808.3 million and is actively working to address its 2029 maturities, with a clear path to improving leverage ratios but no definitive plan yet.

• The company anticipates a more modest Q2 to Q3 adjusted EBITDA increase of $4-$7 million due to the timing of favorable prior year development, and expects MER to remain elevated in Q3 before improving in Q4.

Q & A Highlights

Q: Can you provide more detail on the company's 2027 revenue growth and margin outlook, particularly the puts and takes on the margin side? A: Mario Ramos (CFO) explained that the company expects revenue growth of more than 25% in 2027, driven primarily by Performance Suite business. While the overall margin may appear compressed due to the large revenue base of capitated agreements with single-digit margins, the Performance Suite segment's margins are actually expanding as contracts mature. The company remains committed to delivering meaningful adjusted EBITDA growth, with the midpoint of the 2027 outlook expected to be at or above $150 million, despite headwinds from Medicaid membership declines, exchange attrition, and client-specific market exits.

Q: How is the company's reserving process looking now that several months have passed since the launch of new contracts, and are there any changes in utilization trends, particularly in Part B drugs like oncology? A: Mario Ramos (CFO) stated that the company's reserving is in line with industry trends, with favorable prior period development indicating they are appropriately reserved. On utilization, the company is not seeing anything different from the broader industry, with trend continuing to modulate and improve in stable populations. However, there is noise in some markets due to client decisions on how to serve certain markets, which affects prevalence and mix. Seth Blackley (CEO) added that drugs represent about 75% of total oncology costs, and this has not changed significantly.

Q: Can you quantify the top-line headwinds expected in 2027 from Medicaid work requirements and exchange market exits, and how does this compare to growth from new contracts? A: Mario Ramos (CFO) indicated that the company expects approximately a 20% decline in Medicaid expansion members, translating to a 4% to 5% membership decline in Medicaid. Specialty Tech and Services revenue is expected to be flat to down slightly next year due to membership headwinds. However, this is offset by strong Performance Suite growth, which will drive the majority of the 25%+ revenue growth. The company is staying close to large clients to model client-specific assumptions but cannot provide more granular detail without discussing client-specific information.

Q: What is the current size of the sales pipeline, and has it refilled following recent large deal announcements? A: Seth Blackley (CEO) confirmed that the pipeline has refilled, noting the company has a small market share (less than 2% of the country's lives in Performance Suite) in a very large market. Opportunities span regional Blue plans and regional plans, and notably, a couple of top 10 national plans that were previously not in the pipeline have entered over the last six months. The oncology product continues to gain traction, and the company expects more announcements similar to the new Performance Suite partnership announced this quarter.

Q: Can you discuss the performance and demand for non-oncology conditions like cardiology and MSK? A: Seth Blackley (CEO) explained that oncology often serves as the entry point for new client relationships, but the company sees strong pull-through demand for other specialty conditions like MSK and cardiology. One of the announcements today includes MSK and cardio in a tech and services contract extension. The strategy is to deliver excellent results on the first product, then expand to additional conditions, as clients prefer fewer strategic partners over managing 12-13 separate specialty providers. This pattern has been successful with both large MCO Medicaid partners.

Q: What drove the strong sequential increase in Performance Suite revenue and PMPM rates in Q2, and are contractual risk bands being enforced? A: Mario Ramos (CFO) attributed the sequential revenue increase primarily to the Highmark launch on May 1, with two months of revenue recognized in Q2. The higher PMPM was driven by Highmark's significant Medicare membership. Seth Blackley (CEO) clarified that contractual protections are mechanical and flow through automatically based on actuarial processes, rather than requiring active enforcement. These adjustments can go in either direction depending on acuity and price factors outside the company's control.

Q: Are you seeing any shifts in acuity within the Medicaid membership pool? A: Mario Ramos (CFO) noted that acuity shifts have been more pronounced on the exchange side than in Medicaid, though some shifts have occurred in both. Seth Blackley (CEO) added that these acuity changes trigger automatic contractual adjusters, which currently provide positive cap rate adjustments to the upside. This system ensures fairness for both Evolent and clients, tying clinical work and captured value directly to the company's performance.

Q: Can you help reconcile the Q2 MER of 95% with the full-year guidance of approximately 93%, and what is implied for Q4? A: Mario Ramos (CFO) confirmed that the elevated Q2 MER is expected given the Highmark launch and its conservative reserving, along with the immature Aetna contract. The company expects a gradual improvement of approximately 250 basis points by Q4, driven by completion of the reserve process, clinical improvements (particularly with Aetna), and reversal of new business loads. Highmark will also provide a tailwind on the reserving side in Q4.

Q: Does Medicaid turnover and fragmented claims data from redeterminations and shorter retroactive eligibility windows degrade the ability to identify and engage members early enough to hit targeted clinical savings? A: Seth Blackley (CEO) explained that this does not change the company's ability to perform interventions, as Evolent's model differs from traditional care management. The engagement is focused on specific treatment decisions (e.g., therapeutic medication selection, surgical interventions) over 90-180 day periods, during which members typically remain on their plans. Mario Ramos (CFO) added that reserves follow this process, taking into account contractual protections that shield the company from swings outside its control.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .